Skip to main content

Advertisement

Fig. 3 | Clinical and Translational Medicine

Fig. 3

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Fig. 3

Maximum somatic allele frequency (MSAF) was not correlated with T790M relative mutation purity (RMP) and T790M relative mutation abundance (RMA). a Correlation between MSAF and T790M RMP in the 54 patients (Spearman correlation = − 0.254; P = 0.064). b Correlation between MSAF and T790M RMA in the 54 patients (Spearman correlation = − 0.033; P = 0.814)

Back to article page